A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
What is the purpose of this trial?
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
- Trial withI-Mab Biopharma, Co., Ltd
- Start Date10/12/2020
- End Date02/21/2022
- Last Updated07/15/2021
- Study HIC#2000025819